SHIBO JIANG

Laboratory of Viral ImmunologyThe Lindsley F. Kimball Research Institute

New York Blood Center, 310 East 67th Street, New York, N.Y. 10065Tel: (212) 570-3058, Fax: (212) 570-3099, Email: sjiang@nybloodcenter.org

EDUCATION

1978 Graduation from the First Military Medical University, Guangzhou, China. Major: Medicine.1983 M.S., the First Military Medical University, Guangzhou, China. Major: Immunology. 1995 Ph.D., the Fourth Military Medical University, Xian, China. Major: Microbiology.

PROFESSIONAL APPOINTMENTS

1978-80 Teaching Instructor, Microbiology Dept., the First Military Medical University, Guangzhou, China.1983-85 Lecturer, Immunology Dept., the First Military Medical University, Guangzhou, China.1985-87 Ph.D. Candidate, the Fourth Military Medical University, Xian, China.1987-90 Research Fellow, Laboratory of Cellular Physiology and Immunology, the Rockefeller University,

New York City, USA.1990- Assistant Member (1990-1997), Associate Member (1997-2006), Member (2006-), and Lab Head

(2002-), Lindsley F. Kimball Research Institute of the New York Blood Center, NYC, USA.2000- Visiting Professor, Wuhan University; Fudan University, the First Military Medical University; the

Fourth Military Medical University; Chinese Academy of Military Medical Sciences, China. 2001- Senior Visiting Scholar, Tsinghua University, Beijing, China2004-09 Oversea Assessor, Chinese Academy of Sciences, Beijing, China.2004- Adjunct Professor, the Antiviral Research Center, Southern Medical University, Guangzhou, China.

PATENTS

1. Jiang, S. , Lin, K., and Neurath, A.R. Synthetic peptides as inhibitors of HIV-1. US Patent 5,444,044. Filed March 26, 1992; Issued August 22, 1995 (exclusively licensed to Trimeris for developing T-20).

2. Neurath, A.R., Strick, N., Haberfield, P., and Jiang, S. Method for the prescreening of drugs targeted to the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp120. US Patent 5,230,998. Issued July 27, 1993.

3. Neurath, A.R., Debnath, A.K., Jiang, S., Li, Y.-Y., and Strick, N. Methods for screening of test compounds for inhibiting binding of a CD4-HIV-1 complex to a chemokine receptor. US Patent 5,798,206. Filed January 10, 1997; Issued August 25, 1998.

4. Jiang, S. , Lin, K., and Neurath, A.R. Synthetic peptides as inhibitors of HIV-1 (continuation patent). US Patent 5,840,843. Filed June 7, 1995; Issued on November 24, 1998 (exclusively licensed to Trimeris for developing T-20).

5. Neurath, A.R., Debnath, A.K., and Jiang, S. Beta-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection. US Patent 5,985,275. Filed August 28, 1996, Issued November 16, 1999.

6. Neurath, A.R., Debnath, A.K., and Jiang, S. Methods for preventing the transmission of or treating patients infected with herpesvirus. US Patent 5,952,009. Filed August 28, 1996; Issued September 14, 1999.

7. Neurath, A.R., Jiang, S. and Debnath, A.K. Methods for preventing HIV-1 or HIV-2 infection. US Patent 6,727,240 B1. Filed Oct. 21, 1994. Issued Apr. 27, 2004.

8. Neurath, A.R., Debnath, A.K., Jiang, S. , Strick, A., and Dow, G.J. Methods for decreasing the frequency of transmission of viral infection using cellulose acetate phthalate or hydroxypropyl

methylcellulose phthalate excipients. US Patent 5,985,313. Filed July 8, 1998. Issued November 16, 1999.

9. Neurath, A.R., Debnath, A.K., Jiang, S. , Strick, A., and Dow, G.J. Methods and composition for decreasing the frequency of transmission of HIV, herpesvirus and sexually transmitted bacterial infection. US Patent 6,165,493. Filed October 20, 1998. Issued December 26, 2000.

10. Jiang, S. , and Debnath, A.K. Screening of antiviral compound targeted to the HIV-1 gp41 core structure. US Patent 6,596,497. Filed March 14, 2000. Issued July 22, 2003 (non-exclusively licensed to Japan Tobacco Company for screening HIV entry inhibitors).

11. Jiang, S. , and Debnath, A.K. Compounds for inhibition of HIV infection by blocking HIV entry. US Patent 7,241,803. Filed November 21, 2002. Issued July 10, 2007.

12. Jiang, S. , and He, Y. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus. US Patent 7,629,443. Filed February 7, 2005. Issued December 8, 2009.

13. Jiang, S. , He, Y., and Liu, S. SARS vaccines and method to produce highly potent antibodies. Filed June 2, 2004. US Serial No. 60/576,118 (WO/2005/120565).

14. Jiang, S. , Debnath, A.K., and Lu, H. Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds. Filed June 6, 2006. US Serial No. 60/691,120. (WO/20060/287319)

15. Neurath, A.R., Stone, A., Strick, N., Jiang, S. Rapidly dispersible vaginal tablet that provides a bioadhesive. Filed May 24, 2007. US Serial No. 60/931,548.

16. Jiang, S. , Pan, C. Bifunctional molecules for inhibiting HIV entry. Filed May 28, 2008. US Serial No. 61/056,580.

17. Jiang, S. , Pan, C. Combination therapy of HIV inhibitors targeting gp41. Filed August 13, 2008. US Serial No. 61/088,571.

18. Jiang, S. , Qi, Z., Pan, C. Immunoenhancer-linked oligomeric HIV vaccine. Filed October 17, 2008. US Serial No. 61/106,101.

19. Jiang, S. , Qi, Z., Chen, X., Pan, C. Trimeric HIV fusion inhibitors for treating or preventing HIV infection. Filed February 9, 2009. US Serial No. 61/151,110.

20. Jiang, S. , Du, L. Immunopotentiator-linked oligomeric influenza immunogenic compositions. Filed October 14, 2009. US Serial No. 61/250,442.

GRANTS AWARDED (Peer-reviewed)*

Agency: NIH (R01 AI68003-03)(http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen)Role: Principle InvestigatorTitle: SARS-CoV S Protein Receptor-binding Domain-based Vaccines.Award: $1,578,000 Dates: March 2007 – January 2011.

Agency: NIH (RO1 AI46221-08)(http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen)Role: Principle InvestigatorTitle: Rational Design of HIV Fusion Inhibitors Targeting gp41.Award: $1,958,250 Dates: February 2006 – January 2011.

Agency: NIH (U19 AI076964)(http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen)Role: Program Director and Principle InvestigatorTitle: Anti-HIV Composite Cellulose Acetate Phthalate Film.Award: $6,435,658

2

Dates: September 2004 – August 2009.

Agency: The Outstanding Overseas Chinese Scholars Fund of Chinese Academy of Sciences (2005-2-6)Role: Principle InvestigatorTitle: Mechanism of Action of the Anti-HIV Compounds Targeting the gp41 Core Structure.Award: ¥400,000Dates: February 2006 – January 2009.

Agency: Guangzhou Science and Technology Key Project Foundation (2005Z2-E4041) Role: Principle InvestigatorTitle: Screening and Identification of leading compound of HIV entry inhibitors targeting the

gp41.Award: ¥500,000Dates: July 1, 2005 – June 30, 2008.

Agency: MIRC of NYBC (33212146)Role: Principle InvestigatorTitle: Development of anti-HIV drug candidates targeting gp41.Award: $194,000 Dates: August 2005 – July 2007.

Agency: NIH (R21 AI62402-05A1) Role: Co-PI (PI: Asim K. Debnath)Title: Rational Design of CCR5 Antagonists as Anti-HIV-1 Drugs.Award: $402,836 Dates: June 2004 – January 2006.

Agency: NIH (R21 AI046221-05A1)Role: Principle Investigator Title: Rational design of anti-HIV compounds targeting gp41.Award: $312,176Dates: July 2004 – June 2005.

Agency: NIH (PO1 HD41761)Role: Project Leader of the Project I (Program Director: A. Robert Neurath)Title: In vitro Anti-HIV-1 Activity of CAP (Program title: Anti-HIV Microbicide: Cellulose

Acetate Phthalate). Award: $1,035,596 (total program budget: $4,470,356)Dates: September 2001 – July 2005.

Agency: NIH (RO1 AI46221-04)Role: Principle InvestigatorTitle: Rational Design of Antiviral Compounds to the gp41 Core.Award: $1,161,334 Dates: April 2000 – March 2004.

Agency: NIH (R21 AI54147)Role: Co-PI (PI: Asim K. Debnath)Title: HIV-1 entry inhibitors targeting Phe43 cavity in gp120.Award: $390,000 Dates: September 2002 – August 2004.

Agency: National Nature Science Foundation of China (Outstanding Young Scientist Award: 30028021)

3

Role: Principle InvestigatorTitle: Identification of small cyclic anti-HIV peptides using phage display systems.Award: ¥400,000Dates: December 2000 – November 2003.

Agency: NIH (R21 AI42693)Role: Principle InvestigatorTitle: Antibodies targeting the HIV-1 gp41 Core Structure.Award: $389,712Dates: September 1997 - September 1999.

Agency: The New York Community TrustRole: Principle InvestigatorTitle: Peptides from HIV-1 gp41 for Chemotherapy of AIDS.Award: $100,000 Dates: January 1993 - December 1994.

Agency: NIH (RO1 CA43315)Role: Co-investigator (PI: A. Robert Neurath)Title: HIV-1 ENV Proteins: Targets for antiviral ChemotherapyAward: $1,211,297Dates: December 1992 - November 1996.

Agency: NIH (RO1 AI29373)Role: Co-investigator (PI: A. Robert Neurath)Title: Epitope Mapping of HIV-1 Enhancing AntibodiesAward: $802,563Dates: August 1990 - July 1994.

*Non-peered viewed grants and those from pharmaceutical companies are not listed.

PUBLICATIONS (*corresponding author)

1. Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B., Jiang, S.* (2009). Development of vaccines and therapeutics targeting the spike protein of SARS-CoV (invited review). Nature Rev. Microbiol. 7, 226-236.

2. Du, L., Zhao, G., Chan, C., Li, L., Sun, S., Liu, Z., Guo, H., He, Y., Zhou, Y., Zheng, B.J., Jiang, S.* (2009). Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 393, 144-150.

3. Du, L., Zhao, G., Li, L., He, Y., Zhou, Y., Zheng, B.J., Jiang, S.* (2009). Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 384, 486-490.

4. Pan, C., Cai, L., Lu, H., Qi, Z., Jiang, S.* (2009). Combinations of first and next generation HIV fusion inhibitors exhibits highly potent synergism against Enfuvirtide-sensitive and resistant HIV-1 strains. J. Virol. 83, 7862-7872.

5. Pan, C., Lu, H., Qi, Z., Jiang, S.* (2009). Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS. 23, 639-641.

4

6. Pan, C., Wang, G., Liao, M., Zhang, G.H., Jiang, S.* (2009). High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission. Biochem. Biophys. Res. Commun. 385, 402-407.

7. Pan, C., Jiang, S.* (2009). E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans. PLoS Currents: Influenza. Sept 29:RRN1044.

8. Pan, C., Liu, S., and Jiang, S.* (2009). HIV-1 gp41 fusion intermediate: a target for HIV therapeutics (review). J. Formos. Med. Assoc. In press.

9. Wang, H., Qi, Z., Guo, A., Mao, Q., Lu, H., An, X., Xia, C., Li, X., Debnath, A.K., Wu, S., Liu, S., Jiang, S.* (2009). ADS-J1 inhibits HIV-1 entry by interacting with the gp41 pocket region and blocking the fusion-active gp41 core formation. Antimicrob. Agents Chemother. 53, 4987-4998.

10. Katritzky, A. R., Tala, S. R., Lu, H., Vakulenko, A. V., Chen, Q. Y., Sivapackiam, J., Pandya, K., Jiang, S.*, Debnath, A. K. (2009). Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidin-ylidenemethyl) furans as HIV-1 entry inhibitors. J. Med. Chem. Sep 11. [Epub ahead of print].

11. He, Y., Baker, S.J., MacDonald, A.J., Yu, Y., Cao, L., Li, J., Parhar, R., Heck, S., Hartmann, S., Golenbock, D.T., Jiang, S., Liber, N.A., Semper, A.E., Rosenberg, W.M., Sara Lustigman. (2009). Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth onchocerca volvulus, can directly bind and activate antigen-presenting cells. J. Immunol. 182, 4005-4016.

12. Ma, L., Guo, Y., Yuan, L., Sun, J., Qu, S., Yu, X., Meng, Z., He, X., Jiang, S. , Shao, Y. (2009). Phenotypic and genotypic characterization of HIV-1 CRF07_BC circulating in Xinjiang province of China. Retrovirology. 6, 45.

13. Sun, J., Ma, L., Jiang, S., Shao, Y. (2009). HIV-1 B’/C recombinant (CRF07_BC) in virologic non-controllers elicits neutralizing antibodies against heterologous but not autologous viruses. AIDS Res. Hum. Retroviruses. In press.

14. Tian, X., Qin, B., Lu, H., Lai, W, Jiang, S., Lee, K-H., Chen, C.H., Xie, L. (2009). Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 19, 5482-5485.

15. Wang, Y., Lu, H., Zhu, Q., Jiang, S.*, Liao, Y. (2009). Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg. Med. Chem. Lett. In press.

16. Li, J., Chen, X., Huang, J., Jiang, S.*, Chen, Y.H. (2009). Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. Immunobiol. 214, 51-60.

17. Zhao, G., Lin, Y., Du, L., Guan, J., Sun, S., Sui, H., Kou, Z., Chan, C., Jiang, S., Zheng, B.J., Zhou, Y. (2009). M2e-based polypeptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol. J. In press.

18. Li, J., Lu, L., Wu, F., Chen, X., Jiang, S.*, Chen, Y.H. (2009). The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: involvement in viral fusion. Chinese Sci. Bull. 54, 707-1712.

5

19. Cai, L., Jiang, S.* (2009). Drug-resistant viruses may repair the impaired fitness by mutations outside the drug target site: implication for developing new drugs with improved resistance profile. Future Microbiol. 4, 507-509.

20. Tan, S., Liu, S., and Jiang, S.* (2009). HIV/AIDS related ocular complication (review). Intern. J. Ophthalmol. 9(2), 203-213.

21. Zhang, R.T., Li, X.J., Li, R.M., Hu, Y.P., Jiang, S.B., Liu, S.W. (2009). VIR576 inhibits antigen-specific T cell activation by binding to the transmembrane domain of T cell receptor (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao. 29(10), 1960-1964.

22. Xia, C.L., Jiang, S.B., Liu, S.W. (2009). Research progress on the structure of HIV envelope glycoprotein and related HIV entry inhibitors (review in Chinese). Chin. Pharm. Bull. 2009, 25(8), 991-994.

23. Chen, M., Jiang, S.B., Liu, S.W. (2009). HIV infection-associated host cellular proteins (review in Chinese). Chen. J. Cell. Mol. Immunol. 25(7), 662-664.

24. Li, L., He, L., Lu, H., Qi, Z., Pan, C., Tan, S., Jiang, S.*, Liu, S. (2009). 3-Hydroxyphthalic Anhydride-modified Chicken Ovalbumin Exhibits Potent and Broad Anti-HIV-1 Activity: a Potential Microbicide for Preventing Sexual Transmission of HIV-1. Antimicrob. Agents Chemother. In revision.

25. Du, L., Zhao, G., Chan, C., He, Y., Zhou, Y., Zheng, B.J., Jiang, S.* (2009). A 219-mer recombinant receptor-binding domain of SARS-CoV spike protein induces highly potent immune responses and protection. Viral. Immunol. In revision.

26. He, Y., Cheng, J., Lu, H., Li, J., Hu, J., Qi, Z., Liu, Z., Jiang, S., Dai, Q. (2008). Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Nat. Acad. Sci. USA. 105, 16332-16337.

27. He, Y., Liu, S., Li, J., Lu, H., Qi, Z., Liu, Z., Debnath, A. K., Jiang, S. (2008). Conserved salt-bridge between the N- and C-terminal heptad repeat regions of HIV-1 gp41 core structure is critical for virus entry and inhibition. J. Virol. 82, 11129-11139.

28. He, Y., Chen, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., and Dai, Q. (2008). Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J. Virol. 82(13), 6349-6358.

29. He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S.*, Zhang, L. (2008). Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283 (17), 11126-11134.

30. Qi, Z., Shi, W., Xue, N., Pan, C., Jing, W., Liu, K., Jiang, S.* (2008). Rationally designed anti-HIV peptides containing multi-functional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J. Biol. Chem. 283, 30376-30384.

31. Huang, J.H., Qi, Z., Wu, F., Kotula, L., Jiang, S.*, Chen, Y.H. (2008). Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV-1. J. Biol. Chem. 283(22), 14994-5002.

32. Lu, L., Zhu, Y., Huang, J., Chen, X., Yang, H., Jiang, S.*, Chen, Y.H. (2008). Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J. Biol. Chem. 283(24), 16723-16731.

6

33. Ma, C., Rong, Y., Radiloff, D.R., Datto, M. B., Centeno, B., Bao, S., Cheng, A.W. M., Lin, F., Jiang, S., Yeatman, T.J., Wang, X.F. (2008). Extracellular matrix protein ßig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Gene Dev. 22, 308-321.

34. Zhang, M. Y., Vu, B.K., Choudhary, A., Lu, H., Humbert, M., Ong, H., Alam, M., Ruprecht, R., Quinnan, G., Jiang, S., Montefiori, D.C., Mascola, J.R., Broader, C.C., Haynes, B.F., Dimitrov, D.S. (2008). Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J. Virol. 82, 6869-6879.

35. Xie, L., Guo, H., Lu, H., Zhuang, X., Zhang, A., Wu, G., Ruan, J., Zhou, T., Yu, D., Qian, K., Lee, K. H., Jiang, S.* , (2008). Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-3',4'-di-O-(S)-camphanoyl-4-methyl-(+)-cis-khellactone (3-cyanomethyl-DCK). J. Med. Chem. 51, 7689-7696.

36. Liu, K., Lu, H., Hou, L., Qi, Z., Teixeira, C., Barbault, F., Jiang, S.* , Xie, L., (2008). Design, Synthesis, and Biological Evaluation of N-Carboxyphenylpyrrole Derivatives as Potent HIV Fusion Inhibitors Targeting gp41. J. Med. Chem. 51, 7843-7854.

37. Du, L., Zhao, G., Lin, Y., Sui, H., Chan, C., Ma, S., He, Y., Jiang, S., Wu, C., Yuen, K.Y., Jin, D.Y., Zhou, Y., Zheng, B.J. (2008). Intranasal vaccination with recombinant adeno-associated virus encoding coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J. Immunol. 180, 948-956.

38. Du, L., Zhao, G., Lin, Y., Chan, C., He, Y., Jiang, S., Wu, C. Jing, D.Y., Yuen, K.Y., Zhou, Y., Zheng, B.J. (2008). Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 26, 1644-1651.

39. Du, L., He, Y., Jiang, S., Zheng, B.J. (2008). Development of subunit vaccines against severe acute respiratory syndrome (review). Drugs Today. 44, 63-73.

40. Chien, M.P., Jiang, S., Chang, D.K. (2008). The function of coreceptor as a basis for the kinetic dissection of human immunodeficiency virus type 1 envelope protein mediated cell fusion. FASEB J. 22, 1179-1192.

41. Xiao, W., Du, L., Liang, C., Guan, J., Jiang, S., Lustigman, S., He, Y., Zhou, Y. (2008). Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine. 26, 5022–5029.

42. Shi, W., Qi, Z., Pan, C., Xue, N., Debnath, A., Qie J, Jiang, S.*, Liu, K. (2008). Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs. Biochem. Biophys. Res. Commun. 374, 767–772.

43. Li, J., Chen, X., Jiang, S.*, Chen, Y.H. (2008). Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. Biochem. Biophys. Res. Commun. 376, 60-64.

44. Teixeira, C., Barbault, F., Rebehmed, J., Liu, K., Xie, L., Lu, H., Jiang, S., Fan, B., Maurel, F. (2008). Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors. Bioorg. Med. Chem. 16, 3039-3048.

7

45. Wang, J., Jiang, S. , Shi, H., Lin, Y., Wang, J., Wang, X. (2008). Prolongation of corneal xenotransplant survival by T cell vaccination-induced T regulatory cells. Xenotransplantation. 15(3):164-73.

46. Wang, J., Zhang, L., Tang, J., Jiang, S., Wang, X. (2008). Adoptive transfer of transplantation tolerance mediated by CD4+CD25+ and CD8+CD28- regulatory T cells induced by anti-donor specific T cell vaccination. Transplant Proc. 40(5), 1612-1617.

47. Liu, Y., Su, J., Xiao, H.J., Jiang, S.B., Lu, H., Zhong, W., Wang, L.L., Yang, X.H., Li, S. (2008). Synthesis of benzocycloheptene derivatives as CCR5 antagonists with potent anti-HIV activity. Chin. Chem. Lett. 19 (4), 428-430.

48. Sun, W., Wang, H.T., Xia, C.L., Wu, S.G., Jiang, S.B., Jiang, Z.H., Liu, S.W. (2008). 1,2,6-Tri-O-galloyl-β-D-glucopyranose inhibits HIV-induced cell fusion by targeting gp41 (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao. 28(7):1127-1131.

49. Li, L., Jiang, S., Liu, S. (2008). Microbicides in clinical trials for prevention of sexual transmission of HIV (review in Chinese). Chin. J. Prev. Med. 42(9), 1-4.

50. Liu, S., Li, W., Ding, X., Jiang, S. (2008). Microbicides for preventing the sexual transmission of HIV (in Chinese). Chin. J. Family Planning. 5, 317-320.

51. Wu, Z.L., Zuo, W.L., Sheng, X.T., Li, L., Liu, S.W., Jiang, S., Zhou, W.L. (2008). The Effect of External ATP on Intracellular pH of VK2/E6E7 Cells. Acta Scientiarum Naturalium Universitatis Sunyatseni. 47 (1), 123-124.

52. Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., Meyer. B., Wilhelm, D., Lu, H., Jing, W., Jiang, S., Forssmann, W., Kirchhoff, F. (2007). Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 129, 263-275.

53. Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L.E., Prabakaran, P., Rockx, B., Sidorov, I.A., Corti, D., Vogel, L., Feng, Y., Kim, J.O., Wang, L.F., Baric, R., Lanzavecchia, A., Curtis, K.M., Nabel, G.J., Subbarao, K., Jiang, S., Dimitrov, D.S. (2007). Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Nat. Acad. Sci. USA. 104, 12123-12128.

54. Zhou, J., Lu, L., Yuen, M.F., Lam, T.W., Chung, C.P., Lam, C.L., Zhang, B., Wang, S., Chen, Y., Wu, S.H., Poon, V.K., Ng, F., Chan, C.C., Jiang, S., Yuen, K.Y., Zheng, B.J. (2007). Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. J. Hepatol. 46, 198-205.

55. Liu, S., Jing, W, Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., Jiang, S.* (2007). HIV-1 gp41 C-terminal heptad repeat region contains multiple functional domains. Relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 282, 9612-9620.

56. Liu, S., Wu, S., and Jiang, S.* (2007). HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds (review). Curr. Pharm. Design 13, 143-162.

57. Huang, J.H., Lu, L., Chen, X., Lu, H., Jiang, S.*, Chen, Y.H. (2007). Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of Caveolin-1. J. Biol. Chem. 282, 6143-6152.

58. Huang, J.H., Yang, H.W., Liu, S., Li, J., Jiang, S.*, Chen, Y.H. (2007). The mechanism by which

8

molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium-formation. Biochem. J. 403, 565-571.

59. He, Y., Liu, S., Jing, W, Lu, H., Cai, D., Chin, D.J., Debnath, A.K., Kirchhoff, F., Jiang, S.* (2007). Conserved residue Lys574 in the cavity of HIV-1 gp41 is critical for six-helix bundle formation and virus entry. J. Biol. Chem. 282, 25631-25639.

60. Du, L., Zhao, G., He, Y., Guo, Y., Zheng, B.-J., Jiang, S., and Zhou, Y., (2007). Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 25, 2832-2838.

61. Du, L., Kao, R.Y., Zhou, Y., He, Y., Zhao, G., Wong, C., Jiang, S., Yuen, K.Y., Jin, D.Y., Zheng, B.J. (2007). Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem. Biophys. Res. Commun. 359, 174-179.

62. Jong, A.Y., Wu, C.H., Jiang, S., Feng, L., Chen, H.M., Huang, S.H. (2007). HIV-1 gp41 ectodomain enhance Cryptococcus neoformans binding to HBMEC. Biochem. Biophys. Res. Commun. 356, 899-905.

63. Chen, S., Zhao, X., Tan, J., Lu, H., Qi, Z., Huang, Q., Zeng, X., Zhang, M., Jiang, S., Jiang, H., and Yu, L. (2007). Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity. Eur. J. Pharmacol. 565, 54-59.

64. Su, J., Liu, Y., Zheng, Z.B., Xiao, J.H., Lu, H., Zhong, W., Wangm L.L., Jiang, S.B., Li, S. (2007). Synthesis of aromatic-linked polyamine macrocyclic derivatives as HIV-1 entry inhibitors. Chin. Chem. Lett. 18 (10), 1166–1168.

65. Zhou, J., Lu, L., Zhang, B., Wang, S., Chen, Y., Poon, W.K.M., Jiang, S., Zheng, B.J. (2007). Genetic variations of type I interferon receptor 1 promoter and their association with chronic hepatitis B virus infection (in Chinese). J. Microb. Infect. 2(1), 19-25.

66. Li, M., Li, L., Jiang, S., Zhang, J. (2007). A non-infectious assay for detecting HIV-1 Env-induced cell-cell fusion (in Chinese). J. Jinan Univ. (Med. Sci.) 28(6):576-580.

67. Li, W., Liu, S., Liu, Y., Lu., H., Wang, Y., Jiang, S., Ding, X. (2007). In vitro spermicidal and anti-HIV effects of deoxycholyltyosine (in Chinese). Reprod. Contracept. 27(10): 661-666.

68. Stone, A., and Jiang, S. (2006). Microbicides: stop HIV at the gate (review). Lancet 368, 431-433.

69. Jiang, S.* , Liu, S., and Stone, A. (2006). China needs safe and effective microbicides for preventing the sexual transmission of HIV (commentary). Lancet Infect. Dis. 6, 681-682.

70. He, Y., Li, J., Li, W., Lustigman, S., Farzan, M., and Jiang, S.* (2006). Cross-neutralization of human and palm civet SARS-CoV variants by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 176, 6085-6092.

71. He, Y., Li, J., Heck, S., Lustigman, S., and Jiang, S.* (2006). Antigenic and immunogenic characterization of recombinant baculovirus- severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 80, 5757-5767.

72. He, Y., Li, J., Du, L.,Yan, X., Hu, G., Zhou, Y. and Jiang, S.* (2006). Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike

9

protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 24, 5498-5508.

73. He, Y., Li, J., Jiang, S.* (2006). A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem. Biophys. Res. Commun. 344:106-113.

74. He, L., Ding, Y., Zhang, Q., Che, X., He, Y., Shen, H., Wang, H., Li, Z., Zhao, L., Geng, J., Deng, Y., Yang, L., Li, J., Cai, J., Qiu, L., Wen, K., Xu, X., Jiang, S.* (2006). Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210, 288-297.

75. Gallo, S.A., Wang, W., Rawat, S.S., Jung, G., Waring, A.J., Cole, A.M., Lu, H., Yan, X., Daley, N.L., Craik, D.J., Jiang, S., Lehrer, R.I., Blumenthal, R. (2006). Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J. Biol. Chem. 281, 18787-18792.

76. Meissner, E.G., Zhang, L., Jiang, S., and Su, L. (2006). Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J. Virol. 80, 11019-11030.

77. Vaillant, A., Juteaul, J.M, Lu, H., Liu, S., Lackman-Smith, C., Ptak, R., and Jiang, S.* (2006). Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. 50, 1393-1401.

78. Ye, L., Sun, Y., Lin, J., Bu, Z., Wu, Q., Jiang, S., Steinhauer, D.A., Compans, R.W., Yang, C. (2006). Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. Virology 352, 74-85.

79. Du, L., He, Y., Wang, Y., Zhang, H., Ma, S., Wong, C.K., Wu, S.H., Ng, F., Huang, J.D., Yuen, K.Y., Jiang, S., Zhou, Y.S., Zheng, B.J. (2006). Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology 353, 6-16.

80. Wang, J., Yuan, S. and Jiang, S. (2006). The ribosomal protein L32-2 (RPL32-2) of S. pombe exhibits a novel extraribosomal function by acting as a potential transcriptional regulator. FEBS Letters. 580, 1827-1832.

81. Huang, J.H., Liu, Z.Q., Liu, S., Jiang, S.*, Chen, Y.H. (2006). Identification of the HIV-1 gp41 core-binding motif–HXXNPF. FEBS Letters. 580:4807-4814.

82. Xu, Y., Lu, H., Kennedy, J.P., Yan, X., McAllister, L.A., Yamamoto, N., Moss, J.A., Boldt, G.E., Jiang, S. , Janda, K.D. (2006). Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J. Comb. Chem. 8, 531-539.

83. Boggiano, C., Jiang, S., Lu, H., Zhao, Q., Liu, S, Binley, J., Blondelle, S.E. (2006). Identification of a D-amino acid decapeptide HIV-1 entry inhibitors. Biochem. Biophys. Res. Commun. 347, 909-915.

84. Lu, H., Zhao, Q., Wallace, G., Liu, S., He, Y., Shattock, R., Neurath, A.R., and Jiang, S.* (2006). Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res. Hum. Retroviruses. 22, 411-418.

10

85. Zhang, M.Y., Choudhry, V., Sidorov, I.A., Tenev, V., Vul, B.K., Choudhary, A., Lu, H., Stiegler, G.M., Katinger, H.W., Jiang, S., Broder, C.C., and Dimitrov, D.S. (2006). Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J. Immunol. Methods 317, 21-30.

86. Liu, B.Y., Zhu, P., Jiang, S., Fu, N. (2006). Study of the cyclic peptide binding to HIV-1 gp41 NHR (in Chinese). Immunol. J. 1: 7-10.

87. Liu, B.Y., Zhu, P., Jiang, S., and Fu, N. (2006). Studies on the inhibition of HIV-1-mediated cell Fusion by a synthetic cyclic-peptide (in Chinese). J. Trop. Med. 6, 871-876.

88. Jiang, S.* , He, Y., and Liu, S. (2005). SARS vaccine development (review). Emerg. Infect. Dis. 7, 1016-1020.

89. Liu, S., Lu, H., Niu, J., Xu, Y., Wu, S., and Jiang, S.* (2005). Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 260, 11259-11273.

90. Liu, S., Lu, H, Neurath, A.R., and Jiang, S.* (2005). Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 49,1830-1836.

91. Liu, S., Lu, H., Zhao, Q., He, Y., Niu, J., Debnath, A.K., Wu, S., Jiang, S.* (2005). Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. BBA-Gen. Subjects 1723, 270-281.

92. Liu, S., Wu, S., and Jiang, S.* (2005). Advancement in developing a new class of anti-AIDS drugs: HIV entry inhibitors (review in Chinese). Chin. Pharm. Bull. 21, 1034-1040.

93. He, Y., Lu, H., Siddiqui, P., Zhou, Y., and Jiang, S.* (2005). Receptor-binding domain severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependant epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174, 4908-4915.

94. He, Y., Zhu, Q., Liu, S., Zhou, Y., Yang, B., Li, J., and Jiang, S.* (2005). Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334, 74-82.

95. He, Y., Zhou, Y., Siddiqui, P., and Jiang, S.* (2005). Identification of immunodominant epitopes on the membrane protein of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 43, 3718-3726.

96. He, Y., and Jiang, S.* (2005). Vaccine design for severe acute respiratory syndrome coronavirus (review). Viral Immunol. 18, 327-332.

97. He, Y., and Jiang, S. (2005). Antigenicity and immunogenicity of SARS-CoV (review). eJBio. 1, 21-26.

98. Fichorova, R.N., Zhou, F., Ratnam, V., Atanassova, V., Jiang, S., Strick, N. and Neurath, A.R. (2005). Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob. Agents Chemother. 49, 323-335.

11

99. Zhao, Q., Ma, L., Jiang, S., Lu, H., Liu, S., He, Y., Strick, N., Neamati, N., Debnath, A.K. (2005). Identification of N-Phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339, 213-225.

100. Wang, L.X., Song, H., Liu, S., Lu, H., Jiang, S., Ni, J., Li, H. (2005). Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and α-helix bundle-forming ability of peptide C34. Chembiochem. 6, 1068-1074.

101. MacDonald, A.J., Cao, L., He, Y., Zhao, Q., Jiang, S., and Lustigman, S. (2005). rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine 23, 3446-3452.

102. Zhang, G., Lu, H., Lu, Y., Jiang, S., Chen, Y.H. (2005). Monoclonal antibodies recognizing ELDKWA-epitope of gp41 showed different neutralizing activities against HIV-1. Immunobiology. 210, 639-645.

103. Jiang, S.* (2005). Rapid discovery of peptidic virus fusion inhibitors for urgent treatment and prevention of emerging infectious diseases caused by viruses with type I viral fusion proteins. In Peptides: Biology and Chemistry. Ed by Liu, K.L., Tam, J.P. Science Press USA Inc., Monmouth Junction, NJ, USA. pp191-195.

104. Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante,C.R., Xiong, H., Farmar, J., Debnath, A.K., Tien , P., and Jiang, S.* (2004). Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implication for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 363, 938-947.

105. Liu, S., and Jiang, S.* (2004). High throughput screening and characterization of HIV entry inhibitors targeting gp41: theory and techniques (review). Curr. Pharm. Design. 10, 1827-1843.

106. Jiang, S.* , Siddiqui, P., and Liu, S. (2004). Blocking viral entry: a complimentary strategy for HIV therapy (review). Drug Discovery Today: Therapeutic Strategies. 1, 497-503.

107. Jiang, S.* , Lu, H., Liu, S., Zhao, Q., He, Y., and Debnath, A.K. (2004). N-substituted pyrrole derivatives as novel small molecule human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48, 4349-4359.

108. He, Y., Zhou, Y., Wu, H., Luo, B., Chen, J., Li, W., and Jiang, S.* (2004). Identification of immunodominant sites in the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173, 4050-4057.

109. He, Y., Zhou, Y., Wu, H., Kou, Z, Liu, S., and Jiang, S.* (2004). Mapping of antigenic sites on the nucleocapsid protein of SARS-associated coronavirus. J. Clin. Microbiol. 42, 5309-5314.

110. He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., and Jiang, S.* (2004). Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324, 773-781.

111. He, Y., Zhou, Y., Siddiqui, P., and Jiang, S.* (2004). Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325, 445-452.

12

112. Ding, Y., He, L., Zhang, O, Huang, Z., Che, X., Hou, J.,Wang, H., Shen, H., Qiu, L., Li, Z., Geng, J., Cai, J., Han, H., Li, X., Kang, W., Weng, D., Liang, P., and Jiang, S.* (2004). Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implication for pathogenesis and virus transmission pathways. J. Pathol. 203, 622-630.

113. de Rosny, E., Vassell, R., Jiang, S., Kunert, R., and Weiss, C.D. (2004). Binding of the 2F5 monoclonal antibody to native and fusion-intermediate states of HIV-1 gp41: implications for fusion-inducing conformational changes. J. Virol. 78, 2627-2731.

114. Naicker,K.P., Jiang, S. , Lu, H., Ni, J., Boyer-Chatenet, L., Wang, L.X., Debnath, A.K. (2004). Synthesis and anti-HIV-1 activity of 4-[4-(4,6-Bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenyl azo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives. Bioorg. Med. Chem. 12, 1215-1220.

115. Lu, L., Liu, S., Jiang, S., and Wu S.G. (2004). Tannin inhibits HIV-1 entry by targeting gp41. Acta Pharmacol. Sin. 25, 213-218.

116. Liu, S., Lu, H., Zhao, Q. and Jiang, S.* (2004). Serva blue derivatives inhibit HIV-1 entry. In XV International AIDS Conference (Bangkok, Thailand), pp9-13. Medimond S.r.i., Bologna, Italy.

117. Liu, S., Lu, H, Wu, S., and Jiang, S.* (2004). Polyphenols in teas inhibit HIV-1 infection by blocking virus entry. In Polyphenols Communications 2004 (edited by Hoikkala, A. and Soidinsalo, O). pp 93-94, Gummerus Printing, Jyväskylä, Finland.

118. Liu, B.Y., Zhu, P., Han, Q.T., Jiang, S., Fu, N. (2004). Screening and identification of HIV-1 gp41 C-helix mimotopes displayed on phages (in Chinese). Chin. J. Immunol. 20: 633-636.

119. Chen, Z., Xu, Z.K., Huang, Q.S., Li, Z.D., Jiang, S. (2004). Expression of a trimeric structure domain of the HIV-1 transmembrane glycoprotein and preparation of monoclonal antibodies (in Chinese). Chin. J. Immunol. 20: 487-489.

120. Zhang, J.J., Wu, S.Y., Xu, W., Hou, J.L., Wang, Z.H., Jiang, S.B., and Wu, S.G. (2004). Immunological reaction between the peptides from S1 domain of SARS coronavirus S protein and the sera from SARS patients (in Chinese). Di Yi Jun Yi Da Xue Xue Bao 24: 789-797.

121. Dimitrov, A.S., Rawat, S.S., Jiang, S. and Blumenthal, R. (2003).Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry. 42, 14150-14158.

122. Liu, S., Zhao, Q., and Jiang, S.* (2003). Determination of the HIV-1 gp41 fusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptides. 24, 1303-1313.

123. Liu, S., Boyer-Chatenet, L., Lu, H., and Jiang, S.* (2003). Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. J. Biomol. Screening. 8, 685-693.

124. Liu, S., Wu, Shuguang, and Jiang, S.* (2003). Peptidic HIV fusion inhibitors targeting envelope glycoprotein transmembrane subunit gp41 (review in Chinese). Chin. Pharm. Bull. 19, 1201-1208.

125. Zhao, Q., Lu, H., Schols, D., De Clercq, E., and Jiang, S.* (2003). Development of a cell-based enzyme-linked immunosorbent assay for high throughput screening of human immunodeficiency virus type 1 entry inhibitors targeting the coreceptor CXCR4. AIDS Res. Human Retroviruses 19, 947-955.

13

126. Lu, H., Zhao, Q., Xu, Z., and Jiang, S.* (2003). Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. J. Virol. Methods 107, 155-161.

127. Liu, B.Y., Luo, H.B., Zhu, P., Jiang, S., Fu, N. (2003). Screening and identification of HIV-1 gp41 Core structure epitope from random phage display peptide library (in Chinese). Chin. J. Immunol. 19: 461-472.

128. Tian, H., Lan, L., Jiang, S. , Chen, Y.-H. (2003). Structural characteristics and biological functions of the HIV-1 gp120 V3 region (review in Chinese). Prog. Nature Sci. 13, 11-14.

129. Ernst J.T., Kutzki, O., Debnath, A.K., Jiang, S., Lu, H. and Hamilton, A.D. (2002). Design of a protein surface antagonist based on α-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. 41, 278-281.

130. Jiang, S.* , Zhao, Q. and Debnath, A.K. (2002). Peptide and non-peptide HIV fusion inhibitors (review). Curr. Pharm. Design. 8, 563-580.

131. Xu, Z.K., Wei, L., Wang, L., Wang, H.., and Jiang, S.* (2002). The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. Biochem. Biophys. Res. Commun. 298, 552-558.

132. Zhao, Q., Ernst J.T., Hamilton, A.D., Debnath, A.K., and Jiang, S.* (2002). XTT formazan widely used for detecting cell viability inhibits HIV type 1 by targeting gp41. AIDS Res. Human Retroviruses 18, 989-997.

133. Liu, S., Jiang, S., Wu, Z., Lv, L., Zhang, J., Zhu, Z., and Wu, S. (2002). Identification of an inhibitor of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medical herbs Prunella Vulgaris and Rhizoma Cibotte. Life Sci. 71, 1779-1791.

134. Neurath, A.R., Strick, N., Jiang, S., Li, Y.Y., and Debnath, A.K. (2002). Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of “dead-end” gp41 six-helix bundles. BMC Infect. Dis. 2, 6.

135. Jiang, S.* , Liu, S., Boyer-Chatenet, L., Lu, H., and Zhao, Q. (2002). Tannin inhibits HIV-1 fusion by blocking the gp41 six-helix bundle formation: potential use for preventing sexual transmission of HIV-1. In XIV International AIDS Conference (Barcelona, Spain), pp205-209. Monduzzi Editore, Bologna, Italy. pp205-209.

136. Liu, S., Jiang, S., Liu, B., Wu, Z., Lu, L., Zhang, J., Fu, N., and Wu, S. (2002). Modification and improvement of a screening assay for identification of HIV fusion inhibitors targeting gp41 (in Chinese). Chin. Pharm. Bull. 18 (9), 31-35.

137. Xu, Z., and Jiang, S. (2001). Advance of studies on HIV-1 entry inhibitors (review in Chinese). J. Cell. Mol. Immunol. 17, 401-402.

138. Jiang, S.* (2001). Identification of a small molecular weight anti-HIV-1 compound that interferes with formation of the fusion-active gp41 core. J. Cell. Mol. Immunol. 17, 404-406.

139. Zhao, Q., Xu, Z., Yan, Y., Wang, H., Wu, X., Zhang, F., Liu, Y., Bai, W., Luo, W. and Jiang, S.* (2001). Cloning and expressing of HIV-1 gp41 N and C peptide gene (in Chinese). J. Cell. Mol. Immunol. 17, 484-485.

14

140. Le, Y., Jiang, S. , Hu, J., Gong, W., Su, S., Dunlop, N.M., Shen, W., Li, B., and Wang, J.M. (2000). N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope gp41, is an activator of human phagocytes. Clin. Immunol. 96, 236-242.

141. Shu, W., Liu, J., Ji, H., Radigan, L., Jiang, S., and Lu, M. (2000). Helical interactions in the HIV-1 gp41 core reveals structure basis for the inhibitory activity of gp41 peptides. Biochemistry. 39, 1634-1642.

142. Jiang, S.* , and Debnath, A.K., (2000). A salt bridge between an N-terminal coiled coil of the gp41 core and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem. Biophys. Res. Commun. 270, 153-157.

143. Jiang, S.* , and Debnath, A.K., (2000). Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41 (review). Biochem. Biophys. Res. Commun. 269, 641-646.

144. Jiang, S.* , and Zhang, L. (2000). Studies on antiviral agents targeted to the HIV-1 gp41 core structure (review in Chinese). J. Microb. Infect. 23, 31-36.

145. Jiang, S.* , and Debnath, A.K. (2000). The HIV-1 gp41 core: a target for developing HIV-1 inhibitors (review). Curr. Topics Biochem. Res. 2, 1-17.

146. Jiang, S.* , Lin, K., Li, Y.-Y., and Debnath, A.K. (2000). ADS-J1, an antiviral compound targeted to the HIV-1 gp41 core structure. In XIII International AIDS Conference (Durban, South Africa), pp215-218. Monduzzi Editore, Bologna, Italy.

147. Neurath, A.R., Strick, N., Li, Y.-Y., Radigan, L. and Jiang, S. (2000). A microbicide for the third millenium (cellulose acetate phthalate). In XIII International Conference (Durban, South Africa), pp713-717. Monduzzi Editore, Bologna, Italy.

148. Jiang, S.* , Radigan, L., and Zhang, L (2000). A convenient cell fusion assay for rapid screening for HIV entry inhibitors. Proc. SPIE. 3926, 212-219.

149. Ji, H., Shu, W., Burling, T, Jiang, S. and Lu, M. (1999). Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J. Virol. 73, 8578-8586.

150. Debnath, A.K., Radigan, L., and Jiang, S.* (1999). Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42, 3203-3209.

151. Jiang, S.* , Lin, K., Zhang, L., and Debnath, A.K., (1999). A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods. 80, 85-96.

152. Neurath, A.R., Strick, N., Li, Y.Y., Lin, K, and Jiang, S.* (1999) Design of a “microbicide” for prevention of sexually transmitted disease using “inactive” pharmaceutical excipients. Biologicals 27, 11-21.

153. Debnath, A.K., Jiang, S., Strick, N., Lin, K., Kahl, S.B. and Neurath, A.R. (1999). Anti-HIV-1 activity of carborane derivatives of porphyrins. Med. Chem. Res. 9, 267-275.

154. Jiang, S.* , Lin, K., and Lu, M. (1998). A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 72, 10213-10217.

15

155. Neurath, A.R., Strick, N., Lin, K., Li, Y.-Y., Debnath, A.K. and Jiang, S.* (1998). Microbicide B195. In 12th World AIDS Conference (Geneva, Switzerland), pp239-242. Monduzzi Editore, Bologna, Italy.

156. Jiang, S.* (1997). HIV-1 - co-receptor binding (letter). Nature Med. 3, 367-368.

157. Seppälä, M., Jiang, S., Strick, N., Lin, K., Li, Y.Y., Koistinen, H., Koistinen, R., and Neurath, A.R. (1997). Glycodelins GdA and Gds modified by 3-hydroxyphthalic anhydride inhibit gp120-CD4 binding and HIV-1 infection in vitro. Lab. Invest. 77, 127-130.

158. Neurath, A.R., Debnath, A.K., Strick, N., Li, Y.-Y., Lin, K., and Jiang, S. (1997). 3-Hydroxyph-

thaloyl-ß-lactoglobulin: I. Optimization of production and comparison with other compounds considered for chemoprophylaxis of mucosally transmitted HIV. Antivir. Chem. Chemother. 8, 131-139.

159. Neurath, A.R., Debnath, A.K., Strick, N., Li, Y.-Y., Lin, K., and Jiang, S. (1997). 3-Hydroxyph-thaloyl-ß-lactoglobulin: II. Anti-HIV-1 activity in vitro in environments relevant to prevention of sexual transmission of the virus. Antiv. Chem. Chemother 8, 141-148.

160. Jiang, S.* , Li, Y.-Y., Lin, K., Strick, N., Neurath, A.R., George, K.S., Choudhury, C. and Esmaeli-Azad, B. (1997). Virucidal and antibacterial activities of 3-HP-ß-LG. In Vaccines 97 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp327-330. Cold Spring Harbor Laboratory, New York.

161. Neurath, A.R., Li, Y.-Y., Strick, N., and Jiang, S.* (1996). A herpesvirus inhibitor prepared from bovine whey (letter). Lancet 347, 1703-1704.

162. Neurath, A.R., Jiang, S., Strick, N., Lin, K., Li, Y.-Y.,and Debnath, A.K. (1996). Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nature Med. 2, 230-234.

163. Jiang, S.* , Lin, K., Strick, N., Li, Y.-Y., and Neurath, A.R. (1996). Chemically modified bovine beta-lactoglobulin blocks uptake of HIV-1 by colon- and cervix-derived epithelial cells. AIDS Res. Hum. Retroviruses 13, 461-462.

164. Neurath, A.R.,Strick, N., Jiang, S. , Debnath, A.K., Ralph, H., Li, Y.-Y., and Chou, T.-C. (1996). Expanded diversity of compounds of medicinal interest by chemical transformation of natural products: potential for AIDS prophylaxis and effect on proliferative responses of lymphocytes.In Vaccines 96 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp317-322. Cold Spring Harbor Laboratory, New York.

165. Neurath, A.R., Debnath, A.K., Strick, N., Li, Y.-Y., Lin, K., and Jiang, S. (1995). Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J. Mol. Recogn. 8, 304-316.

166. Jiang, S.* , and Lin, K. (1995). Effect of amino acid replacement, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 gp41 sequence. Peptide Res. 8, 345-348

167. Neurath, A.R., Strick, N., Lin, K., and Jiang, S. (1995). Two partially overlapping antiviral peptides from the external portion of HIV-1 gp41, adjoining the transmembrane region, bind to the gp41 fusion domain (letter). AIDS Res. Hum. Retroviruses 11, 189-190.

168. Neurath, A.R., Strick, N., Lin, K., and Jiang, S. (1995). Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV-1 virions. AIDS Res. Hum. Retroviruses 11, 687-696.

16

169. Debnath, A.K., Jiang, S ., and Neurath, A.R. (1995). Molecular modeling of the V3 loop of the HIV-1 envelope glycoprotein gp120 reveals a possible binding pocket for porphyrins. In QSAR and molecular modeling: concepts, computational tools and biological applications. (F. Sanz, J.Giraldo, and F. Manaut, eds.). pp585-587. J.R. Prous Science Publishers, Barcelona.

170. Neurath, A.R., Strick, N., Lin, K., and Jiang, S. (1995). The HIV-1 glycoprotein gp41 as a target for immunoprophylaxis and chemoprophylaxis. In Vaccines 95 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp183-188.Cold Spring Harbor Laboratory, New York.

171. Jiang, S.* (1995). Advance in studies of antiviral agents against HIV (review in Chinese). J. Microb. Infect. 18, 13-29.

172. Jiang, S.* (1995). The molecular mechanism by which CTLs kill target cells and protect themselves (review in Chinese). J. First Mil. Med. Univ. 15, 4-8

173. Sun, D., Jiang, S., Zheng, L., and Young, J.D.-E. (1994). Endonuclease activation is neither sufficient nor necessary to induce nuclear chromatin condensation in apoptosis. J. Exp. Med. 179, 559-568.

174. Luo, K.-X., Liang, Z.-S., He, H.-T, Zhang, L., Zhu Y.-W., Meng, Q.-H. and Jiang, S. (1994). A complex etiologic connotation of acute non-A, non-B hepatitis in China (letter). J. Hepatol. 20, 916.

175. Debnath, A.K., Jiang, S., Strick, N., Lin, K., Haherfield, P. and Neurath, A.R. (1994). Three dimensional structure activity analysis of a series of porphyrin derivatives as anti-HIV-1 agents targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. J. Med. Chem. 37, 1099-1108.

176. Yu, L.-J., Mao, R.-D., and Jiang, S. (1994). Effects of tubeimoside-1 on HIV-1 core protein p24 production and cytopathogenesis. Acta Pharmacol. Sinica 15, 103-106.

177. Neurath, A.R., Strick, N., Lin, K., Debnath, A.K. and Jiang, S. (1994). Tin protoporphyrin IX used in control of heme metabolism in humans effectively inhibits HIV-1 infection. Antiv. Chem. Chemother 5, 322-330.

178. Neurath, A.R., Strick, N., Lin, K., and Jiang, S. (1994). HIV-1 envelope glycoproteins are unlikely to induce autoimmune response. In Vaccines 94 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp15-22. Cold Spring Harbor Laboratory, New York.

179. Jiang, S.* , Lin, K., Strick, N., and Neurath, A.R. (1993). HIV-1 inhibition by a peptide (letter). Nature 365, 113.

180. Luo, K.-X., Liang, Z.-S., Yang, S. -C., Zhou, R., Meng, Q.-H., Zhu, Y.-W., He, H.-T., and Jiang, S. (1993). Aetiological investigation of acute post-transfusion hepatitis non-A, non-B hepatitis in China. J. Med. Virol. 39, 219-223.

181. Jiang, S.* , Lin, K., Strick, N., and Neurath, A.R. (1993). Inhibition of HIV-1 infection by a fusion domain binding peptide from HIV-1 envelope glycoprotein gp41. Biochem. Biophys. Res. Commun. 195, 533-538.

182. Neurath, A.R., Strick, N., Li, Y.-Y., and Jiang, S. (1993). Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins gp120/gp41. AIDS Res. Hum. Retroviruses 9, 1195-1208.

17

183. Neurath, A.R., Strick, N., and Jiang, S. (1993). Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. Approaches applicable to epidemic HIV-1 strains. Antiv. Chem. Chemother 4, 207-214.

184. Neurath, A.R., Strick, N., and Jiang, S. (1993). Synthetic peptides and antipeptide antibodies as probes to study interdomain interactions in the envelope of HIV-1. In Vaccines 93 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp203-208. Cold Spring Harbor Laboratory, New York.

185. Luo, K.-X., Wang, L.-P., Nie, J., and Jiang, S.* (1992). Is nonresponsiveness to hepatitis B vaccine due to latent hepatitis B virus infection? (letter) J. Infect. Dis. 165, 777-778.

186. Jiang, S.* , and Neurath, A.R. (1992). Potential risks of eliciting enhancing HIV-1 infection of monocytic cells by vaccination with HIV-1 envelope antigens. AIDS 6, 331-332.

187. Neurath, A.R., Strick, N., and Jiang, S. (1992). Synthetic peptides and anti-peptide antibodies as probes to study inter-domain interactions involved in virus assemble: the envelope of the human immunodeficiency virus (HIV-1). Virology 188, 1-13.

188. Luo, K.-X., Zhou, R., Liang, Z.-S., Jiang, S.* (1992). Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. Immunol. Invest. 21, 275-281.

189. Neurath, A.R., Strick, N., Haberfield, P. and Jiang, S. (1992). Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120. Antiv. Chem. Chemother. 31, 55-63.

190. Jiang, S.* , Lin, K. and Neurath, A.R. (1992). Search for domains in envelope glycoproteins of the human immunodeficiency virus type 1 (HIV-1) eliciting antibodies enhancing HIV-1 infection. In Vaccines 92 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp151-155. Cold Spring Harbor Laboratory, New York.

191. Jiang, S.* , Lin, K. and Neurath, A.R. (1991). Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174, 1557-1563.

192. Neurath, A.R., Strick, N., Kolbe, H., Kieny, M.-P., Girard, M. and Jiang, S. (1991). Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1)-II. Synthetic peptides linked to HIV-1 carrier proteins gag and nef. Mol. Immunol. 28, 965-973.

193. Ojcius, D.M., Jiang, S., and Young, J.D.-E. (1991). Cytoplasts from cytotoxic T lymphocytes are resistant to perforin-mediated lysis. Mol. Immunol. 28, 1011-1018.

194. Ojcius, D.M., Muller, S., Hasselkus-Light, C.S., and Young, J.D.-E. and Jiang, S.* (1991). Plasma-associated proteins with the ability to partially inhibit perforin-mediated lysis. Immunol. Let. 28, 101-108.

195. Luo, K.-X., Zhou, R., He, C., Liang, Z.-S., and Jiang, S.* (1991). Hepatitis B virus DNA in sera of virus carries positive exclusively for antibodies to the hepatitis B core antigen. J. Med. Virol. 35, 55-59.

196. Neurath, A.R., Strick, N., Fields, R. and Jiang, S. (1991). Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies. AIDS Res. Hum.Retroviruses 7, 657-662.

18

197. Neurath, A.R., Jiang, S., Strick, N., Kolbe, H., Kieny, M.-P., Muchmore, E. and Girard, M. (1991). Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full length V3 hypervariable loops of HIV-1 envelope glycoproteins gp120. AIDS Res. Hum. Retroviruses 7, 813-823.

198. Neurath, A.R., Haberfield, P., Joshi, B., Hewlett, I.K. and Strick, N. and Jiang, S. (1991). Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed i-mmunoassays. I. The V3 loop of gp120 as target. Antiv. Chem. Chemother 2, 303-312.

199. Neurath, A.R., Strick, N. and Jiang, S. (1991). Recognition of V3 hypervariable loop of HIV-1 gp120 is not determined exclusively by its primary amino acid sequence. In Vaccines 91 (R.M. Chanock, H.S. Ginsberg, F. Brown and R.A. Lerner, eds.), pp15-21. Cold Spring Harbor Laboratory, New York.

200. Ojcius, D.M., Jiang, S. and Young, J.D.-E. (1990). Restriction factors of homologous complement: a new candidate? Immunol. Today 11, 47-49.

201. Jiang, S.B. , Ojcius, D.M., Persechini, P.M., and Young, J.D.-E. (1990). Resistance of cytolytic lymphocytes to perforin-mediated killing: inhibition of perforin-binding activity by membrane proteins. J. Immunol. 144, 998-1003.

202. Ojcius, D.M., Jiang, S., Persechini,P.M., Storch,J., and Young,J.D.-E. (1990). Resistance to the pore forming protein of cytotoxic T cells: comparison of target cell membrane rigidity. Mol. Immunol. 27, 839-845.

203. Young, J.D.-E., Jiang, S., Liu, C.-C., and Hasselkus-Light, C.S. (1990). The lymphocyte pore-forming protein perforin and complement components C8 and C9 share domains that are involved in binding to homologous restriction factor as determined by anti-idiotype antibodies. J. Immunol. Methods 128, 133-142.

204. Jiang, S. , Ojcius, D.M. and Young, J.D.-E (1990). Perforin-binding to cells and lipid membranes determined by a competition assay. J. Immunol. Methods 126, 29-37.

205. Jiang, S. , Hasselkus-Light, C.S., Ojcius, D.M., and Young, J.D.-E. (1990). Purification of a membrane-associated serine esterase from murine cytotoxic T lymphocytes with a single reverse column. Protein Expres. Purif. 1, 77-80.

206. Liu, C.C., Jiang, S., Persechini, P.M., Zychlinsky, A., Clark, W.R., Kaufmann, Y., and Young, J.D.-E. (1989). Resistance of cytolytic lymphocytes to perforin-mediated killing: induction of resistance correlated with increase in cytotoxicity. J. Exp. Med. 169, 2211-2225.

207. Liu, C.C., Detmers, P.A., Jiang, S., and Young, J.D.-E. (1989). A membrane-bound cytotoxin of murine cytolytic lymphocytes related to tumor necrosis factor/cachectin. Proc. Nat. Acad. Sci. USA. 86, 3286-3290.

208. Jiang, S. , Persechini, P.M., Perussia, B., and Young, J.D.-E. (1989). Resistance of cytolytic lympho-cytes to perforin-mediated killing: Murine CTL and human NK cells do not contain functional soluble homologous restriction factor or other specific soluble protective factors. J. Immunol. 143, 1453-1460.

209. Jiang, S. , Persechini, P., Rosse, W.F., Perussia, B., and Young, J.D.-E. (1989). Differential susceptibil-ity of type III erythrocytes of paroxysmal nocturnal hemoglobinuria to lysis mediated by complement and perforin. Biochem. Biophys. Res. Commun. 162, 316-325.

210. Persechini, P.M., Liu, C.-C., Jiang, S., and Young, J.D.-E. (1989). The lymphocyte pore-forming protein perforin is associated with granules by a pH-dependent mechanism. Immunol. Let. 22, 23-27.

19

211. Jiang, S. , Persechini, P.M., Zychlinsky, A., Liu, C.C., Perussia, B., and Young, J.D.-E. (1988). Resistance of cytolytic lymphocytes to perforin-mediated killing: lack of correlation with complement-associated homologous species restriction. J. Exp. Med. 168, 2207-2219.

212. Jiang, S.* , and Li, W.J. (1987). Influence of Ehrlich ascitic carcinoma on immune system: inhibition of host response to thymus-dependent antigen. J. Med. Colleges PLA (in English) 2, 36-39.

213. Jiang, S.* (1987). Advance in neuroendocrinoimmunology (review in Chinese). Shanghai J. Immunol. 7, 165-170.

214. Jiang, S.* (1987). Neuroendocrinoimmunology (review in Chinese). Immunol. J. 2, 140-143.

215. Jiang, S.* (1986). The changes of thymic structure and functions of Ehrlich ascites carcinoma-bearing mice. J. Med. Colleges PLA (in English) 1, 311-326.

216. Jiang, S. , Xiao, J.G., and Li, W.J. (1985). Mechanism of delayed-type hypersensitive change in Ehrlich ascites carcinoma-bearing mice (in Chinese). Chin. J. Clin. Oncol. 12, 238-241.

217. Jiang, S. , Chen, Z.H., and Li, W.J. (1985). Histological change of immune organs of tumor-bearing mice (in Chinese). Cancer Res. Prev. Treat. 12, 9-12.

218. Jiang, S. , Chen, Z.H., and Li, W.J. (1985). The distribution of T lymphocytes in immune organs of tumor-bearing mice (in Chinese). Cancer Res. Prev. Treat. 12, 187-191.

219. Jiang, S. , Zhang, L., and Li, W.J. (1985). The antigen-binding cells in spleen of tumor-bearing mouse (in Chinese). Chin. J. Cancer 1, 14-20.

220. Jiang, S. , Chen, Z.H., and Li, W.J. (1985). Influence of malnutrition on immune system (in Chinese). J. First Mil. Med. Univ. 5, 189-191.

221. Jiang, S. , and Li, W.J. (1985). Influence of Ehrlich ascites carcinoma on cell subpopulations in host thymus (in Chinese). Prog. Biochem. Biophys. 6, 38-40.

222. Jiang, S. , and Li, W.J. (1985). Surface morphological change of thymocytes in Ehrlich ascites carcinoma-bearing mice (in Chinese). Chin. J. Oncol. 7, 342-345.

223. Jiang, S. , Chen, Z.H., and Li, W.J. (1984). The change of synthesis of DNA and RNA in the thymus of tumor-bearing mice (in Chinese). J. First Mil. Med. Univ. 4, 13-16.

224. Jiang, S. , Zhang, L., and Li, W.J. (1984). The reaction of Ehrlich ascites carcinoma-bearing host to thymus-independent antigen (in Chinese). Shanghai J. Immun. 4, 283-286.

225. Jiang,S. (1984). The possible relationship between tumor and thymic atrophy (review in Chinese). Medicine and Philosophy 8, 14-20.

226. Jiang, S. , and Li, W.J. (1984). Thymic atrophy and its effects on immune system (review in Chinese). Foreign Med. Sect. Immunol. 1, 18-22.

227. Jiang, S. (1984). Tumor missile therapy (review in Chinese). Chin. J. Cancer 1, 72.

228. Jiang, S. , Chen, Z.H., and Li, W.J. (1983). Innovation in identification method of T lymphocyte esterase activity (in Chinese). Shanghai J. Immunol. 3, 254-260.

20

229. Jiang, S. , Chen, Z.H., and Li, W.J. (1983). Complex contrast stain of T lymphocyte esterase (in Chinese). Chin. J. Lab. Med. 6, 234-235.

230. Jiang, S. , Chen, Z.H., and Li, W.J. (1983). Effect of acute thymus atrophy on number of T lymphocytes in peripheral blood of Ehrlich ascites carcinoma-bearing mice (in Chinese). Shanghai J. Immunol. 2, 8-10.

231. Jiang, S. , Chen, Z.H., and Li, W.J. (1983). Influence of Ehrlich ascites carcinoma on immune system: IV. Distribution of T lymphocytes in the immune organs of tumor-bearing mice (in Chinese). J. First Mil. Med. Univ. 4, 9-14.

232. Jiang, S. , and Li, W.J. (1983). Influence of Ehrlich ascites carcinoma on immune system: III. Histological changes of the immune organs of tumor-bearing mice (in Chinese). J. First Mil. Med. Univ. 4, 3-8.

233. Jiang, S. , Chen, Z.H., and Li, W.J. (1982). The kinetic change of T lymphocytes in peripheral blood of tumor-bearing mice with acute thymic atrophy (in Chinese). Cancer Res. Prev. Treat. 9, 127-142.

234. Jiang, S. , and Li, W.J. (1980). Ultrastructural change of cytotoxic T lymphocytes after interaction with target cells (review in Chinese). Int. J. Immunol. 1, 34-38.

PROFESSIONAL ACTIVITY

Institutional Service:

1999-08 Member, the Internal Review Board (IRB) of the NYBC.2002- Member, the Patent Committee of the NYBC.2004-07 Member, the Core Facility Review Committee of the LFKRI.2002-03 Member, the Space Committee of the LFKRI.2001-02 Chair, the Research Committee of the LFKRI.1990-02 Member, Ad hoc peer review committees the LFKRI (for faculty promotion).1996-97 Chair, the Seminar Committee of the LFKRI.1991-99 Member, the P3 Committee of the LFKRI.

Service to Professional Publications:

1. Editorial Consultant, The Lancet, 2005.3.14- (http://www.thelancet.com) 2. Executive Guest Editor, Current Pharmaceutical Design, 2002.11.12-2008.12.31 3. Member of Editorial Board, International Journal of Virology, 2005.9.2-2009.1

(http://www.academicjournals.net/2/eb.php?id=2&theme=2&jid=ijv)4. Member of Editorial Board, Electronic Journal of Biology (eJBio), 2005.2.2-2008.2.1 5. Member of Editorial Board, The Open AIDS Journal, 2008.12.3-

(http://www.bentham.org/open/toaidj/EBM.htm)6. Member of International Editorial Board, International Journal of Ophthalmology (IJO), 2006.8.24-

(http://www.world-eye.cn/xsnews/News_View.asp?NewsID=5420)7. Member of Editorial Board, Journal of Medical Universities of PLA (in English)(1986-1990).8. Nature Medicine (ad hoc referee) 9. Nature Technology (ad hoc referee)10. Journal of Experimental Medicine (ad hoc referee)11. PNAS (ad hoc referee)12. Journal of Immunology (ad hoc referee)13. Journal of Virology (ad hoc referee)

21

14. AIDS (ad hoc referee)15. Journal of Pathology (ad hoc referee)16. Journal of Molecular Biology (ad hoc referee)17. Plos Med (ad hoc referee)18. Plos Pathogen (ad hoc referee)19. Plos One (ad hoc referee)20. Journal of Biochemistry (ad hoc referee)21. Antiviral therapy (ad hoc referee)22. JAIDS (ad hoc referee)23. Virology (ad hoc referee)24. Viruses (ad hoc referee)25. Virus Journal (ad hoc referee)26. Retrovirology (ad hoc referee) 27. Journal of General Virology (ad hoc referee)28. Journal of Infectious Diseases (ad hoc referee)29. Journal of Virology Methods (ad hoc referee)30. Virus Immunology (ad hoc referee)31. Genes and Immunity (ad hoc referee)32. FEBS Letter (ad hoc referee)33. Journal of Pharmaceutical Science (ad hoc referee)34. Peptides (ad hoc referee)35. Vaccines (ad hoc referee)36. Gene Therapy (ad hoc referee)37. BBA-General Subjects (ad hoc referee)38. Clinical Chemistry (ad hoc referee)39. Current Medicinal Chemistry (ad hoc referee)40. Virus Research (ad hoc referee)41. AIDS Research and Human Retroviruses (ad hoc referee)42. IUBMB Life (ad hoc referee)43. Cell Physiology and Biochemistry (ad hoc referee)44. Clinical Microbiology Review (ad hoc referee)45. Applied and Environmental Microbiology (ad hoc referee)46. Medical Research Review (ad hoc referee)47. Clinical and Vaccine Immunology (ad hoc referee)48. Journal of Orthopedic Research (ad hoc referee)49. ChemBioChem (ad hoc referee)50. Future Microbiology (ad hoc referee)51. Journal of Formosan Medical Association (ad hoc referee)52. Protein & Cell (ad hoc referee)

Other Professional Service:

Ad hoc Member, grant review study section on Innovative AIDS Vaccines, Center for Scientific Review Special Emphasis Panel, NIH (1998).

Ad hoc Member, grant review study section on In vitro Test Systems for Evaluating Chemotherapies against AIDS, Center for Scientific Review Special Emphasis Panel, NIH (2002).

Member of Abstract Review Committee for the XIV International AIDS Conference at Barcelona, Spain (2002).

Member of Abstract Review Committee for the XV International AIDS Conference at Bangkok, Thailand (2004).

Member, the Scientific Advisory Committee of the International Virology Workshop, Wuhan, China (2004).

22

Ad hoc Member, grant review study section on Innovative Research Topic in Virology, Center for Scientific Review Special Emphasis Panel, NIH (2004).

Member, Overseas Assessor Board for Chinese Academy of Sciences (CAS) (2004 - ). External Reviewer for Canadian Institutes of Health Research (CIHR) (2004). External Reviewer for Chinese National Sciences Foundation (CNSF) (2005 - ). Member, the Scientific Advisory Committees of IDDST-2006, World AIDS Day-2006, IDDST-2007,

IDDST-2008, WSA-2008, 2008 Vaccine Summit (2006-2008), IDDST-2009. Regular Member, AIDS Discovery and Development of Therapeutics (ADDT) Study Section, NIH

(2007-2009)(http://www.csr.nih.gov/Roster_proto/meeting_roster.asp?stdate=3/5/2008&enddate= 3/5/2008&grcode=&srg=ADDT&SRGDISPLAY=ADDT&agsqnum=197706).

External Reviewer for Hong Kong Research Grant Council (RGC)(2008 - ).

SELECTED NEWS REPORTS

1. China Daily, September 26, 1993. A Chinese Scientist Discovered a Peptidic Anti-HIV Drug in the United States (in Chinese).

2. Wen Hui Newspaper (Hong Kong). October 10, 1993. A Chinese Scientist Attacks AIDS – Dr. Shibo Jiang Discovered a New Anti-HIV Drug (in Chinese).

3. PR Newswire - 30 Jan 1996. Lab Tests Show New Milk-Based Compound Prevents HIV Transmission By Blocking Body's HIV Receptor Sites: Inexpensive Compound Holds Potential for Reducing Sexual Transmission of AIDS on A Worldwide Scale. http://www.aegis.com/news/pr/1996/pr960146.html

4. AIDSWeekly Plus, December 7, 1998. AIDS Immunity: MAb Binds HIV's Coiled Coil. http://www.aegis.com/pubs/aidswkly/1998/aw981202.html.

5. AIDSWeekly Plus, March 8, 2004. HIV/AIDS Pathogenesis: Conformation of HIV gp41 during cell entry determined. http://www.aegis.com/default.asp?req=http://www.aegis.com/pubs/aidswkly/2004/AW040305.html

6. U.S. Newswire – March 19, 2004. Scientists from N.Y. Blood Center's Research Institute Identify Peptide with Potential to Inhibit SARS Virus Infection. http://releases.usnewswire.com/GetRelease.asp?id=104-03192004.

7. Yahoo! News. March 19, 2004. Scientists from N.Y. Blood Center's Research Institute Identify Peptide with Potential to Inhibit SARS Virus Infection. http://story.news.yahoo.com/news?tmpl=story&cid=669&ncid=669&e=1&u=/usnw/20040319/pl_usnw/scientists_from_n_y__blood_center_s_research_institute_identify_peptide_with_potential_to_inhibit_sars_virus_infection104_xml.

8. World Journal, March 24, 2004 (volume 1039). Chinese research team discovered anti-SARS agents (in Chinese). http://www.worldjournal.com/wj-chinese-news.php?nt_seq_id=937487&sc_seq_id=120

9. ABC Newsletter. March 26, 2004. Researchers at New York Blood Center’s Lindesley F. Kimball Research Institute use common strategies to combat emerging infectious diseases. Volume 12, p8, 2004. http://www.americasblood.org.

10. Pearson H. News@Nature, May 10, 2004. SARS linked to sweat - Could you catch the disease from a handshake? http://www.nature.com/news/2004/040503/pf/040503-13_pf.html.

11. ABC News Online, May 7, 2004. SARS may spread through sweat. http://www.abc.net.au/news/newsitems/s1103670.htm.

23

12. Yahoo! News, May 7, 2004. SARS Could Spread Via Coughs, Sweat, Urine. http://story.news.yahoo.com/news?tmpl=story&cid=571&ncid=751&e=4&u=/nm/20040507/hl_nm/health_sars_research_dc.

13. The Mirror Post, May 1, 2007. Prevention of Sexual Transmission of HIV Is Urgently Needed. Mrs. Li Ya Mo, Reporter of The Mirror Post in New York.

24